Slides
Page 1
teknova : FINANCIAL RESULTS Q2 : 2026 SLIDE SUPPLEMENT NASDAQ : TKNO August 5 , 2026
Page 2
Forward-looking statements and use of non-GAAP financial measures Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2026 revenue and Free Cash Outflow guidance, and other statements about Teknova’s business prospects, including about Teknova’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,”“predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectationsand beliefs and are subject to risks and uncertainties,all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertaintiesinclude, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which Teknova makes only as of the date hereof, even if they are repeated by Teknova subsequently. Teknova does not intend and shall have no obligationto update, amend, or clarify these forward-looking statements,except as may be required under applicablesecuritieslaws. Additionally, this presentation contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow (Outflow). Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representativeof its ongoing operating performance. Teknova defines Free Cash Flow (Outflow) as cash provided by (used in) operating activitiesless purchasesof property,plant, and equipment. Teknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this presentation because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitutefor, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies. A full reconciliationof these non-GAAP measures to the most comparableGAAP measures is included at the end of this presentation. © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 2
Page 3
Agenda © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 3 • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2026 Outlook Matt Lowell, Chief Financial Officer • Q&A
Page 4
WE MAKE SOLUTIONS POSSIBLE Leading provider of critical reagents for the discovery, development, and commercialization of novel therapies and diagnostics © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 2026E REVENUE GUIDANCE $45-47M 2026E REVENUE GROWTH (MIDPOINT) 14% % REVENUE FROM CGT ~24% NUMBER OF THERAPIES SUPPORTED ~70 CUSTOMER RETENTION RATE 95% NUMBER OF ASSOCIATES (AS OF JUNE 30, 2026) 156 CLINICAL CUSTOMER % GROWTH 25% PROJECT ADJUSTED EBITDA POSITIVE 2027 ACTIVE CUSTOMERS 3,000+ All metrics reflect FY:2025 actuals unless otherwise noted. 2026 figures are guidance/estimates and subject to change. 4
Page 5
Offering a vast range of product types, sizes, pH, and molarities to support a multitude of applications, such as cell lysis, purifying nucleic acids or proteins, washing, resuspending, and analyzing samples, and sample management MOLECULAR BIOLOGY REAGENTS Our products are fundamental to the life sciences industry © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement LIQUID MICROBIAL CULTURE MEDIA AND SUPPLEMENTS Wide variety of liquid media and broths to expand a particular microbial or bacterial cell of interest under controlled conditions, freeze cells, or to conduct media fills for aseptic validation and monitoring AGAR PLATES Extensive selection of standard and specialty pre-poured agar plates for a wide variety of applications including bacteria, fungi, and nematode growth, and environmental monitoring in cleanroom spaces 5
Page 6
~50% Biopharma & Contract Manufacturing~30% Life Science Tools & Diagnostics ~15% Other Market Segments 5% Non-Product Revenue 2025 REVENUE BREAKDOWN Primary End Market Segments © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 6 REVENUE BY END MARKET SEGMENT FY:2025 • ~250 Life Science Tools • ~150 Diagnostic • Academic & Government • Animal Health • Hospitals • Distributors • ~850 Biotech • ~30 Large Pharma • ~200 CDMO/CMOs BIOPHARMA AND CONTRACT MANUFACTURING LIFE SCIENCE TOOLS AND DIAGNOSTICS OTHER MARKET SEGMENTS * Counts based on unique accounts APPROX. *1,000 ACCOUNTS APPROX. *400 ACCOUNTS APPROX. *1,900 ACCOUNTS
Page 7
© 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 7 Revenue by Product Type and Customer End Market 60% LAB ESSENTIALS CATALOG PRODUCTS15% LAB ESSENTIALS CUSTOM PRODUCTS Catalog <5% 15% CLINICAL SOLUTIONSCUS TOM PRODUCTS Total 2024 Revenue by Product Type and End Market LAB ESSENTIALS ~75% CLINICAL SOLUTIONS ~20% OTHER ~5% 2025 REVENUE BREAKDOWN • Lab Essentials: ~75% of 2025 Revenue ▪ Catalog product revenue comprises ~75% ▪ Custom product revenue comprises ~25% (includes RUO+) • Primarily Biopharma, Life Science Tools and Diagnostics customers • Clinical Solutions: ~20% of 2025 Revenue ▪ Catalog product revenue comprises ~10% ▪ Custom product revenue comprises ~90% • Primarily Biopharma and Diagnostic customers in clinical trials • Other: ~5% of 2025 Revenue ▪ Includes services, shipping, and other non-product related revenue
Page 8
2,008 2,754 3,255 2,826 3,045 3,374 2020 2021 2022 2023 2024 2025 © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 8 Historical Customer Metrics by Product Category 1 Improved methodology for identifying unique accounts implemented in 2024. All prior periods restated. Customer is defined as any customer purchasing within the fiscal year. There is a $5,000 minimum threshold for Clinical Solutions customers. Average Revenue per Customer1 Number of Customers1 LAB ESSENTIALS CLINICAL SOLUTIONS 13 21 24 34 48 60 2020 2021 2022 2023 2024 2025 $10,578 $9,871 $9,761 $10,191 $9,486 $9,201 2020 2021 2022 2023 2024 2025 $369 $323 $352 $198 $148 $128 2020 2021 2022 2023* 2024 2025 In Thousands NON-GAAP FIGURES: * 2023 Average Revenue per Clinical Solutions customer would have been $118 thousand excluding a single large order from a diagnostic customer in Q2:24
Page 9
Why we win © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 9 Relative Annual Spend by Account Type in 2025 Catalog Only Custom GMP 44X 1X 25X CATALOG BUSINESS AS A FOUNDATION 1 Illustrative models based on Teknova’s knowledge of competing technologies Others1 Teknova 1 L 10 L 100 L 1,000 L 10,000 L Typical batch size for Emerging Therapies and Diagnostics SMALLER CUSTOM BATCH SIZES Initial Build Sizes for Custom Research and Clinical Orders Others1 Teknova PRODUCTS SHIPPED IN WEEKS MONTHSQuote Production QC TIME FASTER TURNAROUND TIME Time from Order to Shipment for Custom Orders
Page 10
© 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 10 Build complex custom product requests in minutes with Teknova’s interactive reagent assistant NEW AI-POWERED ASSISTANT Build●TekTM Custom Configurator 3 minutes Build a complete custom order with just a few clicks in one guided session 3 days Submit your configuration and our team returns a quote in 2-3 business days 30 years Proven custom reagent manufacturing experience behind every order Evolution of our original Build●Tek buffer configurator provides complete guidance on formulation, format, manufacturing grade, QC testing, and more: • Assistant is trained on 30 years of Teknova’s manufacturing processes and know-how • Eliminates need for multiple rounds of inputs between the developer and Teknova technical team, which could take weeks and be error-prone • Configurations start with as much – or as little – as the developer has, and supports the upload of existing files, formulations, or literature • Developers can design multiple products at once • Additional features and functionality to come
Page 11
Q2:26 Financials
Page 12
© 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 12 KEY HIGHLIGHTS • Total first quarter revenue up 18% compared to the same period in prior year • Lab Essentials increased 18% compared to the same period in prior year • Clinical Solutions increased 18% compared to the same period in prior year Q2:2026 Revenue Highlights $7.8 $9.2 $2.1 $2.4 Q2:2025 Q2:2026 Revenue by Category ($M) Lab Essentials Clinical Solutions Other $10.3 $12.2 18% y/y
Page 13
38.7% 40.1% Q2:2025 Q2:2026 Gross Margin (%) Q2:2026 Income Statement Highlights 1 Adjusted EBITDA is non-GAAP and adds back stock-based compensation and any qualified non-recurring items to EBITDA $7.4 $7.8 Q2:2025 Q2:2026 Total OpEx ($M) ($0.8) ($0.7) Q2:2025 Q2:2026 Adjusted EBITDA1 ($M) ($0.07) ($0.06) Q2:2025 Q2:2026 Diluted EPS ($) © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 13
Page 14
© 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 14 Q2:2026 Cash Flow and Balance Sheet Highlights 1 Free Cash Flow equals cash provided by (used in) operating activities less purchases of property, plant, and equipment ($2.3) ($0.6) Q2:2025 Q2:2026 Free Cash Flow1 ($M) $0.2 $0.1 Q2:2025 Q2:2026 Capital Expenditure ($M) Cash, Cash Equivalents, and Short-Term Investment was $17.4M as of June 30, 2026
Page 15
Quarterly Financial Trends 1 Gross Margin in Q3:24 excludes non-recurring, non-cash charges related to the expired and excess inventory ($2.8M) 2 Adjusted EBITDA is non-GAAP and adds back stock-based compensation and any qualified non-recurring items to EBITDA ($3.8) ($2.6) ($5.0) ($3.2) ($2.5) ($0.8) ($1.6) ($1.8) ($2.0) ($0.7) Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 Adjusted EBITDA2 ($M) 15 ($6.7) ($3.0) ($2.4) ($1.5) ($4.3) ($2.3) ($2.4) ($0.8) ($3.6) ($0.6) Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 Free Cash Flow3 ($M) 3 Free Cash Flow equals cash provided by (used in) operating activities less purchases of property, plant, and equipment $8.9 $7.8 $7.5 $7.8 $8.0 $7.4 $7.2 $7.4 $8.1 $7.8 $10.2 $7.9 $7.5 $7.8 $8.0 $7.4 $7.2 $7.9 $8.1 $7.8 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 Total OpEx ($M) Recurring Non-Recurring 24% 29% 30% 23% 31% 39% 31% 32% 34% 40% Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 Gross Margin1 (%) © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement
Page 16
2026 Outlook and Capital Runway GUIDANCE • Raising fiscal 2026 outlook for revenue and improving outlook for Free Cash Outflow • Anticipate total revenue of $45 million to $47 million for fiscal year ending December 31, 2026 (“2026”), up 14% y/y at the midpoint • Targeting Free Cash Outflow of less than $8 million for 2026 CAPITAL RUNWAY ASSUMPTIONS • Estimate annualized revenue range of $52-57 million to achieve Adjusted EBITDA break-even by the end of 2027 • Expect sufficient liquidity to reach cash flow positive with organic growth strategy, assuming: • Average low double-digit revenue growth • Average 70% contribution margin on additional revenue • Limited annual OpEx growth • ~$2 million per year of capital expenditure © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 16 ADJUSTED EBITDA POSITIVE BY END OF 2027
Page 17
Supplemental Non-GAAP Reconciliations
Page 18
ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (unaudited) (in thousands) Non-GAAP Reconciliations © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 18